{'fraction_non_alphanumeric': 0.034764826175869123, 'fraction_numerical': 0.019427402862985686, 'mean_word_length': 5.006134969325154, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Kinetics of [methyl-11C]thymidine in patients with squamous cell carcinoma of the head and neck.

Thymidine labelled with a position emitter and imaging by positron emission tomography has been suggested to measure tumour proliferation in vivo non-invasively. The present study presents a compartmental model which describes the behavior of [methyl-11C]thymidine in tumour tissue and allows quantification of the data using a proliferation parameter (PP). In nine patients with squamous cell carcinoma of the head and neck, 11C-activity over the tumour and the adjacent blood vessels was measured. The median PP without correction for blood pool activity was found to be 8.61 10(-4) min(-1). With correction this parameter changed from -14% to +40%. We found no correlation between either sex or tumour differentiation and PP. The described model can be used to quantitate [methyl-11C]thymidine uptake in human tumours. Indivdual correction for tumour blood volume is mandatory.